Clinical Trial

Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.

Study acronym: GLID-HF
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Evaluating the safety and efficacy of glimepiride in patients with type 2 diabetes and chronic heart failure with reduced ejection fraction--a multicenter randomized controlled study.
Trial Details
NCT Number NCT07288749
Lead Sponsor Tongji Hospital
Collaborators: Shanghai Zhongshan Hospital, Nanjing Medical University, Second Xiangya Hospital of Central South University, Huaxi Hospital, Zhongnan Hospital, Xiangya Hospital, Beijing Anzhen Hospital, The First Affiliated Hospital of Air Force Medicial University, Chinese Academy of Medical Sciences, Fuwai Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Anhui Provincial Hospital, Southwest Medical University, First Hospital of China Medical University, Wuhan Central Hospital, Tianjin Medical University
Conditions Type 2 Diabetes Mellitus (T2DM), Chronic Heart Failure (CHF)
Enrollment 1,484 participants
Start Date 2026-01-01
Primary Completion 2030-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-17